Icon Partners with Taiwanese University to Further Trial Advancements

By Zachary Brennan

- Last updated on GMT

Icon teams with Taiwan Hospital
Icon teams with Taiwan Hospital

Related tags Clinical trial

CRO momentum in Asia is picking up as Icon has partnered with a clinical research centre at the National Taiwan University Hospital to accelerate drug development on the Chinese island.

Under the terms of the agreement, the National Clinical Trials Research Centre (NCTRC) and Icon will collaborate on study start-up, site feasibility, key site and investigator selection and patient recruitment. 

This is a long-term commitment between Icon and NCTRC​,” Wei Ming Goh, VP of Icon’s Asia-Pacific division, told Outsourcing-Pharma.com. “Icon already has a strong position in Asia, with operations in 13 countries…we can further accelerate timelines for study start-up and patient recruitment which will benefit our customers and also enhance the Taiwanese clinical trials industry​.”

Icon isn’t the first CRO to set up shop in Taiwan. US CRO Chiltern set up its own legal entity​ on the island in 2012 because client demand was so high, while QPS formed a joint venture​ to take a stab at the region and Parexel purchased a Taiwanese firm​ back in 2007.

Almost two years ago, six Asian CROs, including Taiwan’s StatPlus​, also formed an alliance to compete with the Western CROs operating in the region.

Icon Partnership Details

As far as what the partnership will specifically focus on, there does not seem to be one dominant type of clinical trial or therapeutic area.

This collaboration is not limited to any particular therapeutic area​,” Goh said. “The 10 leading causes of death in Taiwan are cancer, heart disease, cerebrovascular disease, pneumonia, diabetes, accidents, lower respiratory illness, hypertensive disease, chronic liver disease, and nephrotic syndrome and nephritis​. 

Due to the prevalence of these diseases and consequently the access to patients, studies associated with these therapeutic areas may be more prevalent than others​,” he added.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers